Contents

Search

izokibep

Indications: - investigational agent for treatment of psoriatic arthritis Dosage: - injection - 160 mg of weekly or biweekly - 80 mg dose every 4 weeks Mechanism of action: - IL-17A inhibitor

General

disease-modifying antirheumatic agent (DMARD)

References

  1. Gever J Izokibep Marches on for Psoriatic Arthritis. - Early phase III data cement case for novel IL-17A inhibitor. MedPage Today June 16, 2024 https://www.medpagetoday.com/meetingcoverage/eular/110670